Pharmaceutical manufacturers face intensifying federal and state scrutiny over speaker programs and patient support programs as enforcement agencies deploy increasingly sophisticated, data-driven investigative tools.
The federal Anti-Kickback Statute remains the primary legal mechanism for regulating these programs, prohibiting the knowing and wilful offering, paying, soliciting, or receiving of remuneration to induce referrals reimbursable by federal healthcare programs.
False Claims Act liability attaches whenever Anti-Kickback Statute violations taint claims submitted to federal healthcare programs, creating significant financial exposure for manufacturers operating in this space.
The current enforcement climate is operating at a historic high, with the False Claims Act generating $6.8 billion in total recoveries in fiscal year 2025 alone.
The Department of Justice Fraud Section reported $15 billion in alleged losses and 194 individuals charged during that same period, underlining the aggressive posture of federal prosecutors.
Of the $6.8 billion in FCA recoveries last fiscal year, an estimated $2.4 billion, approximately 35%, came directly from pharmaceutical manufacturer settlements and judgments.
The launch of the Health Care Fraud Data Fusion Center alongside the 2025 National Health Care Fraud Takedown signals a decisive shift toward proactive, technology-driven, multi-agency enforcement rather than reliance on whistleblower-initiated investigations.
State-level activity is escalating in parallel, with Texas recently pursuing multiple manufacturers regarding drug and hub support programs, demonstrating increasingly aggressive enforcement postures at the state level.
The DOJ has made clear that pharmaceutical manufacturers remain a top FCA enforcement priority, as evidenced by the re-launch of the DOJ-FCA Working Group and the agency’s public pronouncements accompanying its annual FCA statistics.
For speaker programs, compliance teams must assess whether engagements deliver genuine educational value, particularly given HHS-OIG’s November 2020 Special Fraud Alert, which identified a series of suspect characteristics subject to government scrutiny.
HHS-OIG indicated that its investigations have repeatedly revealed that HCPs receive generous compensation to speak at programs offered under circumstances not conducive to learning or to audiences with no legitimate reason to attend.
Programs held at high-end restaurants, entertainment venues, or sports venues raise immediate red flags, and enforcing spending caps, prohibiting alcohol, and selecting appropriate venues all serve to reduce risk.
Speaker honoraria must reflect fair market value for services rendered and must not take into account the volume or value of prescriptions the speaker has written or is expected to write.
Patient support programs in oncology and rare disease present a particularly complex landscape, as patients frequently face severe side effects that can lead to treatment discontinuation or dose reductions.
HHS-OIG has issued favourable opinions for support arrangements tied to REMS compliance, free companion diagnostic testing, bridge drug programmes, and modest in-kind support such as free eye drops to manage ocular toxicity.
Conversely, HHS-OIG has issued unfavourable opinions where manufacturers proposed providing substantial financial support for fertility services or paying third-party fees for services that hospital customers would otherwise bear themselves.
A critical feature of permissible patient support programmes is the complete absence of any economic benefit flowing to the prescribing physician, as arrangements conferring independent financial value on prescribers carry significant enforcement risk.
Recent DOJ and Texas Attorney General press releases dated February 19, 2026 and June 29, 2026 highlight the ongoing risk that in-kind reimbursement support arrangements may create at the state level.
Patient support offered selectively to high-prescribing physicians may attract HHS-OIG and DOJ scrutiny, and manufacturers should ensure support is distributed based on patient need rather than prescriber volume.
Pharmaceutical manufacturers must treat every patient support programme and speaker engagement as a potential enforcement target, build compliance infrastructure accordingly, and pressure-test business solutions against risk factors identified by regulators.